Krystal Biotech, Inc. (NasdaqGS: KRYS)
Health Care · Biotechnology · US
$356.19
+4.23% today · +142.7% 1Y
Krystal Biotech, Inc. (NasdaqGS: KRYS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.54B and employs 295 people.
Over the last twelve months the share price has gained 142.7%, trading between 136.73 and 382.54.
Tweenvest scores Krystal Biotech, Inc. across four factors: quality 67/100, value 28/100. Its strongest factor is quality.
KRYS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.54B
- Revenue (TTM)
- $440.48M
- P/E
- 44.72
- EPS
- 7.97
- Dividend yield
- —
- Beta (5Y)
- 0.54
- 52-week high
- $382.54
- 52-week low
- $136.73
- Avg volume (3M)
- —
- Shares outstanding
- 29.60M
- Employees
- 295
- Next earnings
- —
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
- ISIN
- US5011471027
- Founded
- 2016
- Listed since
- Sep 20, 2017
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.